Randomized trial demonstrates risk reduction of kidney decline in diabetes patients, suggesting efficacy of dulaglutide.
Treatment with 1.5 mg DU weekly was associated with a clinically relevant risk reduction of ≥40% eGFR decline or ESKD compared with IG daily, particularly in the macroalbuminuria subgroup of participants with T2DM and moderate-to-severe CKD.
No takes yet. Share an insight, caveat, or question.
Tuttle et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: